Perennial Partners
Private Equity Venture Capital Est. 2000
AUD 550M
Estimated FUM
- Type
- Private Equity
- HQ
- Sydney, New South Wales, Australia
- Founded
- 2000
- Focus
- Healthcare
About
Perennial Partners is a house of specialist investment teams. The Perennial Private Investments (PPI) team partners with innovative high growth private companies. Through our Perennial Ventures and Perennial Private to Public Opportunities Funds we are a flexible partner for entrepreneurs, providing capital to businesses from early in their journey all the way through to a public listing and beyond.
Strategies
Growth Equity
Breadth not publicly established
Venture Capital
Breadth not publicly established
Public Equity
Breadth not publicly established
Buyout
Breadth not publicly established
Investment Focus
Investment size
AUD 1M - AUD 20M
Reported investment size. Actual commitments may vary by stage, ownership and follow-on participation.
Focus Areas
Stages
Growth Public / Listed Series B
Focus
Healthcare
Investment Geographies
Primary Markets
Australia
Coverage
Multi-country (Oceania) Regions
Oceania
Coverage is a guide only.
Location
Headquarters
Sydney, New South Wales, Australia
Office Presence
1 country
Australia
1 known office
Sydney, New South Wales, Australia (HQ)
People also viewed
Tritium Partners
Tritium Partners is a private equity firm focused on buyouts of growth companies in the lower middle market. Tritium's investment approach emphasizes acquiring majority positions in profitable companies and creating long-term value through internal growth initiatives and acquisitions, with a particular focus on three core sectors: internet and information services, asset-light supply chain and logistics, and differentiated financial and business services. We also create platform companies by combining smaller businesses in order to establish a strong financial profile, a compelling service offering, and an enthusiastic customer base from which to execute on our growth strategies. Tritium targets high-growth companies with strong management team. These businesses are typically generating $2m to $15m EBITDA at the time of our investment.
Graphite Capital
Graphite Capital is a UK mid-market private equity firm focused on three core sectors: health & pharma, education, and data & tech-enabled services, investing in companies valued between £30 million and £150 million.
Genesis Capital
Genesis Capital is a leading lower mid-market private equity firm focused on the healthcare sector. We are active investors who work together with management teams to unlock growth in healthcare businesses that have the potential to be industry leaders.
• Healthcare experts: We firmly believe healthcare investing is best done by healthcare specialists. We live and breathe it and stick to what we know best.
• Business builders: We are business builders at heart and know what it takes to operate and grow lasting businesses. We find we get the best results are when we not only invest capital, but also our time and expertise to step-change a business's growth.
• Strong partners: We are business builders at heart and know what it takes to operate and grow lasting businesses. We find we get the best results are when we not only invest capital, but also our time and expertise to step-change a business's growth.
Forward Consumer Partners
US private equity firm founded in 2023 investing in lower-middle-market consumer brands, partnering with leaders to build powerful brands that make beloved products.
Emigrant Capital
Emigrant Capital provides long-term equity and equity-like capital to mid-market businesses in the United States. We focus on cash flow positive businesses generating $2 to $12 million EBITDA, although we also can participate in selective turnaround opportunities. We invest in both minority and majority equity positions.
Emigrant Capital is the private equity arm of Emigrant Bank, the largest family owned bank in the United States.
Ellerston JAADE Growth Fund
Ellerston JAADE Private Assets Fund is dedicated to private investments.
We focus on investing in technology companies in the growth stage of development, as well as qualifying pre-IPO companies.
By providing patient capital, mentoring management, and implementing value creation strategies, we seek to help our investees reach their full potential while maximising outcomes for investors.